MicroRNA-221 targets PTEN to reduce the sensitivity of cervical cancer cells to gefitinib through the PI3K/Akt signaling pathway (Q38826622)

6 September 2017

title

MicroRNA-221 targets PTEN to reduce the sensitivity of cervical cancer cells to gefitinib through the PI3K/Akt signaling pathway (English)

1 reference

6 September 2017

1 reference

cervix uterine cancer

1 reference

Juan Du

1

1 reference

6 September 2017

LiNa Wang

2

1 reference

6 September 2017

ChenXi Li

3

1 reference

6 September 2017

HuiLun Yang

4

1 reference

6 September 2017

YuanBo Li

5

1 reference

6 September 2017

Haiyang Hu

6

1 reference

6 September 2017

Hui Li

7

1 reference

6 September 2017

ZongFeng Zhang

8

1 reference

6 September 2017

language of work or name

1 reference

19 October 2015

1 reference

6 September 2017

1 reference

6 September 2017

volume

37

1 reference

6 September 2017

issue

3

1 reference

6 September 2017

page(s)

3939-3947

1 reference

https://scigraph.springernature.com/pub.10.1007/s13277-015-4247-8

6 September 2017

exact match

0 references

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4247-8

Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4247-8

A randomized trial comparing concurrent chemoradiotherapy with single-agent cisplatin versus cisplatin plus gemcitabine in patients with advanced cervical cancer: An Asian Gynecologic Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4247-8

A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4247-8

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4247-8

Human papilloma virus (HPV)-E6/E7 and epidermal growth factor receptor (EGF-R) protein levels in cervical cancer and cervical intraepithelial neoplasia (CIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4247-8

A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4247-8

Role of microRNA221 in regulating normal mammary epithelial hierarchy and breast cancer stem-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4247-8

Clinical significance of miR-221 and its inverse correlation with p27Kip¹ in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4247-8

E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via β-catenin-Egr1-mediated PTEN expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4247-8

MicroRNAs: novel regulators in the hallmarks of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4247-8

miR-133a inhibits cervical cancer growth by targeting EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4247-8

MicroRNA-373 functions as an oncogene and targets YOD1 gene in cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4247-8

MiR-221/222 promote human glioma cell invasion and angiogenesis by targeting TIMP2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4247-8

MicroRNA-221 governs tumor suppressor HDAC6 to potentiate malignant progression of liver cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4247-8

The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4247-8

Targeting the phosphoinositide 3-kinase pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4247-8

Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4247-8

Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4247-8

Epidermal growth factor receptor regulates MT1-MMP and MMP-2 synthesis in SiHa cells via both PI3-K/AKT and MAPK/ERK pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4247-8

MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4247-8

miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4247-8

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4247-8

EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4247-8

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4247-8

Unique microRNA expression profiles in cervical cancer.

21 January 2018

1 reference

12 December 2020

A prospective phase II study of topotecan (Hycamtin®) and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer

1 reference

12 December 2020

Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women.

1 reference

12 December 2020

Improved treatment for cervical cancer--concurrent chemotherapy and radiotherapy

1 reference

12 December 2020

Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, p27(kip1), p57(kip2), and PUMA.

1 reference

12 December 2020

Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis.

1 reference

12 December 2020

A dynamic interplay between alternative polyadenylation and microRNA regulation: implications for cancer (Review).

1 reference

12 December 2020

EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers

1 reference

12 December 2020

Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer

1 reference

12 December 2020

10.1007/S13277-015-4247-8

Identifiers

DOI

1 reference

Dimensions Publication ID

6 September 2017

1042712885

0 references

1 reference